Literature DB >> 21917755

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

Francesca Brambilla1, Francesca Lavatelli, Dario Di Silvestre, Veronica Valentini, Rossana Rossi, Giovanni Palladini, Laura Obici, Laura Verga, Pierluigi Mauri, Giampaolo Merlini.   

Abstract

Considering the important advances in treating specific types of systemic amyloidoses, unequivocal typing of amyloid deposits is now essential. Subcutaneous abdominal fat aspiration is the easiest, most common diagnostic procedure. We developed a novel, automated approach, based on Multidimensional Protein Identification Technology, for typing amyloidosis. Fat aspirates were obtained from patients with the most common systemic amyloidoses (ALλ, ALκ, transthyretin, and reactive amyloidosis), with Congo red score more than or equal to 3+, and nonaffected controls. Peptides from extracted and digested proteins were analyzed by Multidimensional Protein Identification Technology. On semiquantitative differential analysis (patients vs controls) of mass spectrometry data, specific proteins up-represented in patients were identified and used as deposit biomarkers. An algorithm was developed to classify patients according to type and abundance of amyloidogenic proteins in samples; in all cases, proteomic characterization was concordant with fibril identification by immunoelectron microscopy and consistent with clinical presentation. Our approach allows reliable amyloid classification using readily available fat aspirates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917755     DOI: 10.1182/blood-2011-07-365510

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  35 in total

1.  TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients.

Authors:  Marco Luigetti; Amelia Conte; Alessandra Del Grande; Giulia Bisogni; Francesca Madia; Mauro Lo Monaco; Luca Laurenti; Laura Obici; Giampaolo Merlini; Mario Sabatelli
Journal:  Neurol Sci       Date:  2012-05-17       Impact factor: 3.307

2.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

3.  Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.

Authors:  Kanji Miyazaki; Shigeo Kawai; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2015-06-27       Impact factor: 2.490

Review 4.  Approach to the Diagnosis of Amyloidosis.

Authors:  Richa Juneja; H P Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-09       Impact factor: 0.900

5.  Application of confocal laser scanning microscopy for the diagnosis of amyloidosis.

Authors:  Chiara Castellani; Marny Fedrigo; Anna Chiara Frigo; Mila Della Barbera; Gaetano Thiene; Marialuisa Valente; Fausto Adami; Annalisa Angelini
Journal:  Virchows Arch       Date:  2017-02-20       Impact factor: 4.064

Review 6.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

7.  Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.

Authors:  Julie A Vrana; Jason D Theis; Surendra Dasari; Oana M Mereuta; Angela Dispenzieri; Steven R Zeldenrust; Morie A Gertz; Paul J Kurtin; Karen L Grogg; Ahmet Dogan
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

8.  Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors:  G Palladini; P Milani; A Foli; M Vidus Rosin; M Basset; F Lavatelli; M Nuvolone; L Obici; S Perlini; G Merlini
Journal:  Leukemia       Date:  2014-07-25       Impact factor: 11.528

Review 9.  Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.

Authors:  M Hasib Sidiqi; Morie A Gertz
Journal:  Blood Cancer J       Date:  2021-05-15       Impact factor: 11.037

10.  Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.

Authors:  Komei Tanaka; Eric E Essick; Gheorghe Doros; Kahraman Tanriverdi; Lawreen H Connors; David C Seldin; Flora Sam
Journal:  J Am Heart Assoc       Date:  2013-03-12       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.